Clinical Trial · NCT06147037

A Phase 1, First-in-human, Multicentre, Open-label, Dose Escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Overview

This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of [225Ac]-FPI-2068, [111In]-FPI-2107, and FPI-2053 in metastatic and/or recurrent solid tumors (HNSCC, NSCLC, mCRC, PDAC).

Sponsor

Fusion Pharmaceuticals, Inc.

Phase

Phase 1

Contacts

Clinical Trials Fusion Pharmaceuticals Clinical Operations

clinicaltrials@fusionpharma.com

1 (888) 506-4215

ClinicalTrials.gov

NCT06147037

Eligibility

Inclusion

Adequate organ function
Histologically/cytologically confirmed solid tumor, metastatic, locally advanced recurrent or inoperable
Measurable diseases as defined by RECIST v1.1
Progressed disease despite treatment, standard therapy not available contradicted not tolerable or no standard therapy
ECOG performance status 0 or 1

Exclusion

Prior anti-cancer therapy unless adequate washout and recovery from toxicities
Previous treatment with any systemic radiopharmaceutical
Uncontrolled pleural effusion, pericardial effusion, ascites requiring drainage
Contraindications to or inability perform the imaging procedures required in study
Radiation therapy within 28 days prior to the first dose of Indium

Patient Education

Patient education not yet provided.

Publications

Publications not yet provided.

Locations

Loading…